Therapies After Progression on Enfortumab Vedotin and Pembrolizumab: Navigating Second-line Options for Metastatic Urothelial Carcinoma in the New Treatment Landscape.
Eur Urol Focus
; 10(2): 231-233, 2024 Mar.
Article
em En
| MEDLINE
| ID: mdl-38797658
ABSTRACT
There is no clear standard-of-care treatment for patients with metastatic urothelial carcinoma following progression on enfortumab vedotin and pembrolizumab, although multiple regimens are available, including platinum-based chemotherapy, sacituzumab govitecan, and erdafitinib for selected patients. Clinical trials will be important in informing decisions on the best treatment.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Bexiga Urinária
/
Carcinoma de Células de Transição
/
Progressão da Doença
/
Anticorpos Monoclonais Humanizados
/
Anticorpos Monoclonais
Limite:
Humans
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article